Clinical Trial

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-E9D,LUCAR-E9K, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-23.
Status change: Not Yet Recruiting → Recruiting 2025-08-15
Trial Details
NCT Number NCT07093411
Lead Sponsor Beijing GoBroad Hospital
Collaborators: First Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Xi'an Jiaotong University, Anhui Provincial Hospital
Conditions B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory
Enrollment 48 participants
Start Date 2025-08-05
Primary Completion 2028-08 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-20